You appear to be offline. Some data may be unavailable until your connection is restored.
Description
AbbVie Inc. is a research‑focused biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines and biologics. Its portfolio spans immunology drugs such as Humira, Skyrizi and Rinvoq, oncology therapies including Imbruvica and Venclexta, neuroscience products like Vraylar and migraine treatments, as well as aesthetics brands such as Botox. AbbVie operates in the global pharmaceutical and healthcare sector, emphasizing innovative therapies for complex, chronic diseases. The firm is regarded as a leading U.S. biotech firm, noted for its blockbuster immunology franchise and a growing pipeline across multiple therapeutic areas.
Quarterly EarningsQuarterly earnings results, including reported and estimated earnings per share (EPS), for the most recent fiscal quarters.Surprise compares reported EPS with the prior estimate.
| Quarter | DateReport date | EPSReported EPS |
|---|---|---|
| Q3 FY26 | Oct 30, 2026 | — |
| Q2 FY26 | Jul 31, 2026 | $3.65 |
| Q1 FY26 | Apr 29, 2026 | $2.65 |
| Q4 FY25 | Feb 4, 2026 | $2.71 |
| Q3 FY25 | Oct 31, 2025 | $1.86 |
Stay ahead of ABBV earnings
Get reminders ahead of ABBV's next earnings report, so you always know when results are coming.